Par Drugs and Chemicals Limited

NSEI:PAR 주식 보고서

시가총액: ₹3.0b

이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

Par Drugs and Chemicals 과거 수익 실적

과거 기준 확인 5/6

Par Drugs and Chemicals은 연평균 24.8%의 비율로 수입이 증가해 온 반면, Pharmaceuticals 산업은 수입이 증가했으며, 연간 17%였습니다. 매출은 연평균 16.4%의 비율로 증가했습니다. Par Drugs and Chemicals의 자기자본이익률은 16.9%이고 순이익률은 15.2%입니다.

주요 정보

22.5%

수익 성장률

22.3%

EPS 성장률

Pharmaceuticals 산업 성장17.5%
매출 성장률15.6%
자기자본 수익률17.0%
순이익15.3%
최근 수익 업데이트30 Jun 2024

최근 과거 실적 업데이트

Recent updates

Improved Earnings Required Before Par Drugs and Chemicals Limited (NSE:PAR) Stock's 29% Jump Looks Justified

Apr 16
Improved Earnings Required Before Par Drugs and Chemicals Limited (NSE:PAR) Stock's 29% Jump Looks Justified

Here's Why We Think Par Drugs and Chemicals (NSE:PAR) Might Deserve Your Attention Today

Apr 05
Here's Why We Think Par Drugs and Chemicals (NSE:PAR) Might Deserve Your Attention Today

Do Par Drugs and Chemicals' (NSE:PAR) Earnings Warrant Your Attention?

Nov 03
Do Par Drugs and Chemicals' (NSE:PAR) Earnings Warrant Your Attention?

If EPS Growth Is Important To You, Par Drugs and Chemicals (NSE:PAR) Presents An Opportunity

May 19
If EPS Growth Is Important To You, Par Drugs and Chemicals (NSE:PAR) Presents An Opportunity

Does Par Drugs and Chemicals (NSE:PAR) Deserve A Spot On Your Watchlist?

Mar 17
Does Par Drugs and Chemicals (NSE:PAR) Deserve A Spot On Your Watchlist?

Do Par Drugs and Chemicals's (NSE:PAR) Earnings Warrant Your Attention?

Oct 22
Do Par Drugs and Chemicals's (NSE:PAR) Earnings Warrant Your Attention?

Investors Shouldn't Be Too Comfortable With Par Drugs and Chemicals' (NSE:PAR) Robust Earnings

Aug 11
Investors Shouldn't Be Too Comfortable With Par Drugs and Chemicals' (NSE:PAR) Robust Earnings

Here's Why We Think Par Drugs and Chemicals (NSE:PAR) Is Well Worth Watching

Jul 14
Here's Why We Think Par Drugs and Chemicals (NSE:PAR) Is Well Worth Watching

Is Par Drugs and Chemicals Limited (NSE:PAR) An Attractive Dividend Stock?

Mar 31
Is Par Drugs and Chemicals Limited (NSE:PAR) An Attractive Dividend Stock?

Are Strong Financial Prospects The Force That Is Driving The Momentum In Par Drugs and Chemicals Limited's NSE:PAR) Stock?

Mar 05
Are Strong Financial Prospects The Force That Is Driving The Momentum In Par Drugs and Chemicals Limited's NSE:PAR) Stock?

Chairman of the Board & MD Falgun Savani Just Bought A Handful Of Shares In Par Drugs and Chemicals Limited (NSE:PAR)

Feb 06
Chairman of the Board & MD Falgun Savani Just Bought A Handful Of Shares In Par Drugs and Chemicals Limited (NSE:PAR)

Here's Why I Think Par Drugs and Chemicals (NSE:PAR) Might Deserve Your Attention Today

Jan 10
Here's Why I Think Par Drugs and Chemicals (NSE:PAR) Might Deserve Your Attention Today

How Does Par Drugs and Chemicals Limited (NSE:PAR) Fare As A Dividend Stock?

Dec 13
How Does Par Drugs and Chemicals Limited (NSE:PAR) Fare As A Dividend Stock?

수익 및 비용 분석

Par Drugs and Chemicals 수익 창출 및 지출 방식. 최근 보고된 수익 기준, LTM 기준.

수익 및 매출 내역

NSEI:PAR 수익, 비용 및 수입 (INR Millions )
날짜수익수익G+A 비용R&D 비용
30 Jun 24953146560
31 Mar 24956145550
31 Dec 23973142530
30 Sep 23962127520
30 Jun 23952115510
31 Mar 23957113490
31 Dec 22933103460
30 Sep 22873106420
30 Jun 2282191420
31 Mar 2275192410
31 Dec 21692112410
30 Sep 21686112410
30 Jun 21631115400
31 Mar 21608116400
31 Dec 2057988380
30 Sep 2055083380
30 Jun 2055465400
31 Mar 2055848410
31 Dec 1953241380
30 Sep 1950620360
30 Jun 1948423360
31 Mar 1946325360
31 Mar 1842415350
31 Mar 1748818330
31 Mar 163334220

양질의 수익: PAR 은 높은 수익을 보유하고 있습니다.

이익 마진 증가: PAR 의 현재 순이익 이익률 (15.2%) 작년보다 높습니다 (11.8%).

잉여현금흐름 대 수익 분석

과거 수익 성장 분석

수익추이: PAR 의 수익은 지난 5년 동안 매년 24.8% 씩 크게 증가했습니다.

성장 가속화: 지난 1년간 PAR 의 수익 증가율( 27.9% )은 연간 평균( 24.8% 초과합니다. ).

수익 대 산업: 지난 1년간 PAR 수익 증가율( 27.9% )은 Pharmaceuticals 업계 18% 초과했습니다.

자기자본 수익률

높은 ROE: PAR 의 자본 수익률( 16.9% )은 낮음으로 간주됩니다.

자산 수익률

고용 자본 수익률

과거 성과가 우수한 기업 찾기

7D

1Y

7D

1Y

7D

1Y